The timely tracking of a global launch
Managing ATUs with staggered launches across multiple markets can be tricky. Research Director Rebecca Davies outlines how we approach the challenge.
A key challenge faced by our clients running global tracking studies is when to track. For a product yet to launch, commercialisation can vary by market by months or years. Typically, data is collected at 3 key stages - a time point prior to launch, a couple of months post launch and then at regular intervals. The issue is - how can ATU projects be managed when a product is due to be commercialised at different time points across markets?
Top 10 tips for conducting effective UX research
Creating a new digital asset? Make sure you do your research first. Different stakeholders, whether they are healthcare professionals, consumers, patients or caregivers, exhibit different behaviours and needs online. Ensure your asset offers the optimum user experience by following our 10 top tips for conducting effective UX research
Like, Like, Like: How pharmaceutical companies can harness the power of social media insights
Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As the popularity and diversity of platforms increases, so too does their utility for healthcare market research. Combined with the continuous stream of user-generated content, advances in research technology now allow marketers to tap into social media data to understand more about the healthcare landscape.
Living with rheumatoid arthritis: How social stigma, unemployment and the rise of mental illness affects patient attitudes toward their disease in Japan
Rachel Arthurs explores differing social attitudes towards RA between patients living in Japan and patients in Europe and Canada.
In recent months, Research Partnership’s Mariel Metcalfe alongside her Living With team have been conducting an in-depth multi-country study into the experiences of those living with rheumatoid arthritis. The study was carried out amongst patients in Europe, Canada and Japan to gain insights into the ways in which patients react to their diagnosis, manage their treatment and the possible support they hope to see in the future. An interesting trend that emerged during the course of the research was the differing social attitudes towards illness between patients living in Japan compared to those in Europe and Canada. Japanese patient’s daily lives are impacted differently to those in other countries, possibly due to pre-existing stigmas and social attitudes. In this article, we examine these differences, consider why they might occur and propose how we can use this understanding to improve global treatment solutions and marketing of existing and pipeline pharmaceuticals.
The future of food allergy? The emergence of targeted allergy treatments
Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment
In recent years, there has been a noticeable shift in the increased public awareness of allergy-related complications both within the United Kingdom and globally. In 2010, Allergy UK estimated that at least 44% of British adults were currently suffering from at least one allergy, a statistic that only continues to rise steadily each year. In the United States, Statista reported that approximately 20% of American adults in 2017 were suffering from an allergy or food intolerance.